Jefferies Financial Group Inc. Has $7.05 Million Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Jefferies Financial Group Inc. reduced its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 79.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,156,642 shares of the company’s stock after selling 8,157,091 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Taysha Gene Therapies were worth $7,052,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TSHA. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 2nd quarter worth approximately $31,000. ST Germain D J Co. Inc. raised its stake in Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after acquiring an additional 6,350 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TSHA. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a report on Thursday, December 4th. Wells Fargo & Company increased their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.91.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $4.59 on Tuesday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -13.91 and a beta of 1.02. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The stock has a 50 day moving average price of $4.77 and a two-hundred day moving average price of $4.47. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48.

Insider Activity at Taysha Gene Therapies

In related news, CEO Sean P. Nolan sold 136,789 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $4.71, for a total value of $942,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares of the company’s stock, valued at $4,740,327.69. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 598,623 shares of company stock valued at $2,822,188 over the last 90 days. Insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.